Context: Most methods for assessing dietary intake have considerable measurement error. Dietary biomarkers are objective tools for dietary assessment. Dietary biomarkers of dietary patterns have not been well described, despite modern dietary guidelines endorsing dietary patterns. Objective: This systematic review sought to describe the dietary biomarkers commonly used to assess dietary patterns, and the novel biomarkers of dietary patterns identified by exploratory studies. Data Sources: MEDLINE, Embase, Cochrane Central, PreMEDLINE, and CINAHL databases were searched. Data Extraction: Data extraction and bias assessment were undertaken in duplicate. Data Analysis: A qualitative approach was applied, without statistical analysis. Conclusion: In controlled settings, dietary biomarkers of single nutrients or of individual foods or food groups are commonly used to assess compliance with dietary patterns. However, currently, there are no dietary biomarkers or biomarker profiles that are able to identify the specific dietary pattern that has been consumed by an individual. Future work should seek to validate novel dietary biomarkers and biomarker profiles that are indicative of specific dietary patterns and their characteristics. A dietary biomarker panel consisting of multiple biomarkers is almost certainly necessary to capture the complexity of dietary patterns. Systematic Review Registration: PROSPERO registration no. CRD42019129839.

Quantitative rankings of multiple dietary patterns for their effects on non-communicable disease (NCD) biomarkers is lacking and would inform primary prevention strategies. Accordingly, a network meta-analysis (NMA) was conducted to compare and rank the effects of different dietary patterns on NCD biomarkers, and associations of dietary patterns’ underlying macronutrient composition with NCD biomarkers were determined by a nutritional geometry approach. Randomised controlled trials (RCTs) were eligible for inclusion if they enrolled healthy participants, employed food-based dietary pattern interventions without energy restriction, and reported NCD biomarker outcomes. NCD biomarkers were included as an outcome if ≥10 trials were available. A systematic search of five electronic databases identified 4008 records. Sixty-eight articles from 59 RCTs reporting lipids, glycemic, and inflammatory biomarkers were included for quantitative syntheses. Risk-of-bias was predominantly categorized as low or having some concerns, and confidence-of-evidence low. Relative to western habitual diet, the Mediterranean, Dietary Approaches to Stop Hypertension (DASH), dietary guidelines-based, plant-based, and low-fat diets reduced low-density lipoprotein cholesterol (mean difference range: −0.29 to −0.17 mmol/L), total cholesterol (−0.36 to −0.24 mmol/L), and apolipoprotein B (−0.11 to −0.07 g/L) (all p < 0.05); the Paleo, plant-based and dietary guidelines-based diets reduced homeostasis model assessment of insulin resistance (−0.95 to −0.35, all p < 0.05). No dietary pattern ranked consistently highest. The Paleo diet received the highest all-outcomes-combined average Surface Under the Cumulative Ranking Curve value (67%), followed by DASH (62%) and Mediterranean diets (57%), whereas western habitual diet was lowest (36%). Our findings were independent of macronutrient composition, highlighting the significance of dietary pattern-level analysis.

As a gas signal molecule, hydrogen sulfide (H₂S) can participate in many physiological and biochemical processes such as seed germination and photosynthesis regulation. In order to explore the regulatory effect of H₂S on the growth of Miscanthus sacchariflorus under Cd stress and to provide sufficient theoretical basis for the complex action of H₂S and energy plants to remediate soil pollution. In this experiment, the effects of different concentrations of H₂S (10, 25, 50, 100, 300, 400, 500 μmol·L^-1 (μM)) pretreatment on the growth index, lipid peroxidation degree, chlorophyll (Chl) content, osmoregulation substance content, antioxidant enzyme activity and non-enzymatic antioxidant content of M. sacchariflorus under Cd stress (50 μM) were studied. The results showed that under Cd stress, the reactive oxygen species (ROS) content in the body of M. sacchariflorus was unbalanced, and the growth were severely inhibited, the activities of antioxidant enzymes, such as catalase (CAT) and superoxide dismutase (SOD) significantly decreased, and the content of osmoregulation substance, ascorbic acid (AsA) and glutathione (GSH) significantly increased. With the increase of H₂S concentration, its effect on resisting Cd stress can be shown as "low concentration promotes, high concentration inhibits". When the concentration of H₂S ≤ 300 μM, although there was no significant difference in Cd content compared with Cd treatment alone, it can regulate the activities of peroxidase (POD), SOD, glutathione reductase (GR) and monodehydroascorbate reductase (MDHAR), increase the content of osmoregulation substances, oxidized glutathione (GSSG), and the transformation rate of AsA and dehydroascorbic acid (DHA) to reduce the oxidative damage and improve the growth and photosynthetic indicators of plants; when the concentration of H₂S ≥ 400 μM, Cd content in the ground and root decreased significantly, but the transport factor increased significantly, the growth status of M. sacchariflorus were more severely inhibited by the combined stress of H₂S and Cd. In this experiment, it was found that the concentration of H₂S pretreatment ≤ 300 μM could regulate the growth of M. sacchariflorus under Cd stress to normal level, and when the treatment concentration was 50 μM, the effect was the best. It will provide a new idea for the treatment of contaminated soil by energy plants.

Non-communicable diseases (NCDs) are a major global health and economic burden. Precision medicine has merged as a promising approach for treating NCDs by tailoring health interventions to individual profiles. Despite rapid advances, its effective implementation remains slow. This systematic review aimed to examine the implementation landscape for delivering precision medicine interventions, services, or programs for NCDs, focusing on barriers, facilitators, strategies, and outcomes. Comprehensive searches were performed in PubMed, Embase, CINAHL, and Web of Science until November 2024. The search strategy comprised of four key concepts, i.e. precision medicine, NCDs, implementation, and public health. Articles published from 2014 onwards were included. Extracted data included study characteristics, populations, precision medicine intervention details, and information related to implementation. Relevant data were coded to implementation science frameworks and taxonomies. These included the updated Consolidated Framework for Implementation Research (CFIR 2.0), Expert Recommendations for Implementing Change (ERIC), and Proctor’s outcomes framework. The QuADs tool was used to assess the risk of bias of included studies. A total of 10,039 records were identified, with 8,684 abstracts and 463 full texts screened. Of these, 68 studies met the inclusion criteria. While 64 studies reported implementation determinants [i.e. barriers (n = 61) and/or facilitators (n = 40)], approximately two-thirds proposed or implemented strategies that were primarily based on intuition. Key barriers identified included ‘access to knowledge and information’ (n = 34) and ‘work infrastructure’ (n = 21) within the Inner Setting, and ‘financing’ (n = 20) within the Outer Setting. While financial burdens were clearly attributed to patients and healthcare settings, there was less clarity and strategic direction regarding potential funding sources to support implementation strategies. Implementation Outcomes were reported in 46 instances, with Adoption being the most frequent. Service Outcomes, particularly Effectiveness, were generally positive, as were patient outcomes, primarily, mortality and morbidity. Despite growing interest in precision medicine for treating NCDs, implementation evidence remains theoretically fragmented, making it difficult to identify implementation success patterns. Future efforts adopting targeted strategies and robust outcome evaluation, guided by implementation science, are needed to support effective integration of precision medicine into routine healthcare.

Introduction Genomic diagnostics have accelerated therapeutic and preventative breakthroughs in oncology and cancer genetics. Despite increased access, the implementation of genomics-based care faces serious fragmentation and scalability issues due to a lack of system support. The Precision Care Initiative aims to develop a novel and scalable Precision Care Clinic (PCC). It is designed to coordinate precision medicine in oncology and streamline decision support for referring oncologists and geneticists. The PCC will enhance quality of care through multifaceted, patient-centred communication. It will also improve translational capacity by integrating team expertise in precision oncology, implementation science, clinical informatics, cancer genetics, health economics and patient-reported measures. Methods and analysis This programme uses a type I and type II hybrid effectiveness-implementation trial design sequentially. The complex clinical intervention is precision oncology—matching the targeted treatment or risk management strategy to the right patient, based on their genomic, cancer staging, environmental, lifestyle and biological characteristics, etc. The service intervention is the PCC, providing centralised multidisciplinary review to facilitate shared decision-making with clinicians for the provision of optimal precision oncology care for their patients. The implementation intervention is the co-designed implementation platform—applying evidence-based implementation approaches and Learning Health System principles to enhance feasibility and sustainability. All adult patients across Australia referred to the PCC (n=est. 100–150/year), and healthcare professional interest holders involved in the delivery of precision oncology services, are eligible to participate. Over the study course, phase I involves using a mixed-methods approach to inform iterative co-design and pilot testing of the first PCC with an accompanying implementation platform, and a suite of outcome measures to assess effectiveness; phase II (hybrid type I) includes the implementation of the PCC and evaluation of the outcome measures designed in phase I; phase III (hybrid type II) involves a co-design of local adaptations and testing the effectiveness of the PCC model nationally. Ethics and dissemination The study received ethical approval from the St Vincent’s Hospital Human Research Ethics Committee (2023/ETH00373). Study results will be presented at relevant conferences and published in peer-reviewed journals. Trial registration number NCT06077110

Introduction Cardiac rehabilitation is known to reduce morbidity and improve quality of life in people living with heart disease, however, adherence, access and completion of these programmes is suboptimal. Peer support may offer an opportunity to close this service gap. The aim of the study is to determine whether the effectiveness of a digital peer support programme for people living with heart disease is effective in improving social connectedness, clinical and patient-reported outcomes and experience measures. Methods and analysis Heart2Heart is a community-based randomised controlled trial with 6 months follow-up for the primary outcome and 6 and 12 months for secondary outcomes. Approximately 752 adults with a diagnosis of heart disease in the past 12 months will be recruited from the general community and Australian cardiac rehabilitation programmes. Control group will participate in usual care, while intervention group will have access to a 6 months intervention that enables peer support via an interactive mobile application, in addition to usual care. The intervention includes online discussion groups, access to resources and facilitated conversations with health professionals. Primary outcome is social connectedness at 6 months follow-up. Secondary outcomes (6 and 12 months) will be all-cause/cardiovascular disease hospital admissions, all-cause mortality, lifestyle (sufficiently physically active, not smoking, sufficient fruit and vegetable consumption), proportion taking prescribed medications and health service utilisation (medical appointments, cardiac rehabilitation, participation in any other in-person peer support activities). Patient-reported outcome and experience measures including self-efficacy, quality of life, satisfaction and programme engagement will be analysed at 6 months. Process measures will include application analytics, barriers and facilitators to engagement with the intervention from participant’s perspective. An intention-to-treat analysis will be used. Ethics and dissemination Ethical clearance was obtained from Western Sydney Local Health District Ethics Committee. Heart2Heart has potential to improve social connectedness and provide a valuable addition to traditional cardiac rehabilitation. Trial registration number ACTRN12624000386538.